Accessibility statement

The Finnish Medicines Agency Fimea seeks to guarantee the accessibility of each of its websites in accordance with the Act on the Provision of Digital Services (306/2019).

The Act on the Provision of Digital Services is the national implementation of the EU Accessibility Directive (Directive 2016/2102 of the European Parliament and the Council of the European Union on the accessibility of the websites and mobile applications of public sector bodies).

This accessibility statement pertains to the and -websites.

Compliance status

The website meets accessibility requirements. The website will be audited for accessibility in autumn 2023, and any shortcomings detected will be rectified in 2024.

Making this accessibility statement:
This statement was prepared on 1 March 2023.
The statement is based on Fimea’s self-assessment.

Feedback and contact information

Accessibility feedback can be sent to the Fimea Registry.

Contact information: [email protected]
P.O. Box 55, 00034 FIMEA
Switchboard: +358 29 522 3341

Enforcement procedure

If you notice accessibility issues on this site, you should first send feedback to the website administrator. It may take up to 14 days to receive a reply. If you are not satisfied with the response you receive, or if you do not receive any response within two weeks, you can notify the supervisory authority of the matter.

Contact details of the supervisory authority

Regional State Administrative Agency for Southern Finland
Accessibility Control Unit
Switchboard: +358 295 016 000